A phase II study of encorafenib in combination with binimetinib in patients with metastatic BRAF-mutated thyroid cancer in Japan
CONCLUSIONS: Treatment with encorafenib plus binimetinib met the primary endpoint criteria and demonstrated clinical benefit in patients with BRAFV600E-mutated thyroid cancer regardless of its histological type, such as DTC or ATC, with no new safety concerns identified. Encorafenib plus binimetinib could thus be a new treatment option for BRAF V600-mutated thyroid cancer.PMID:38343359 | DOI:10.1089/thy.2023.0547
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Authors: Makoto Tahara Naomi Kiyota Hiroo Imai Shunji Takahashi Akihiro Nishiyama Shingo Tamura Yasushi Shimizu Shigenori Kadowaki Ken-Ichi Ito Masahiro Toyoshima Yoshinori Hirashima Shinji Ueno Iwao Sugitani Source Type: research
More News: Cancer | Cancer & Oncology | Endocrinology | Japan Health | Study | Thyroid | Thyroid Cancer | Toxicology